trending Market Intelligence /marketintelligence/en/news-insights/trending/4HZsHP6N0IzVZSczZu0ylg2 content esgSubNav
In This List

India's Zydus Healthcare acquires six drug brands from Merck

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


India's Zydus Healthcare acquires six drug brands from Merck

India's Zydus Healthcare Ltd. acquired six brands from Merck & Co. Inc. that fall under the categories of men's health, women's health, wound management and cardiovascular therapy.

The brands are Deca-Durabolin, Durabolin, Sustanon, Multiload, Sicastat and Axeten, which had sales of 840 million Indian rupees in 2015.

The companies did not disclose the financial terms of the acquisition.

As of Dec. 28, US$1 was equivalent to 68.21 Indian rupees.